Santhera Pharmaceuticals Holding AG SANN

SWX: SANN | ISIN: CH0027148649 13/11/2024

8,420 CHF (-0,36%)

(-0,36%) 13/11/2024

Grafiek Santhera Pharmaceuticals Holding AG

Grafiek Santhera Pharmaceuticals Holding AG

1 dag1d -0,36%
1 week1w -4,32%
1 maand1m -7,47%
3 maanden3m -1,52%
6 maanden6m -8,48%
1 jaar1j -15,97%
5 jaar5j -27,79%

Santhera Pharmaceuticals Holding AG in het nieuws

Toon enkel gratis nieuws

12 november 2024 · Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar · Persbericht

1 oktober 2024 · Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism · Persbericht

24 september 2024 · Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy · Persbericht

12 september 2024 · Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update · Persbericht

10 september 2024 · Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe · Persbericht

13 augustus 2024 · Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026 · Persbericht

31 juli 2024 · Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary · Persbericht

18 juni 2024 · Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting · Persbericht

18 juni 2024 · Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even · Persbericht

10 juni 2024 · Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix · Persbericht

Profiel Santhera Pharmaceuticals Holding AG

CEO: Dario Eklund

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe